vs
MYOMO, INC.（MYO）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是MYOMO, INC.的1.2倍（$14.0M vs $11.4M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -33.6%，领先43.4%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -5.9%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-2.4M），过去两年MYOMO, INC.的营收复合增速更高（73.9% vs 24.6%）
MYOMO INC.是一家医疗科技企业，研发和生产可穿戴肌电矫形设备，帮助上肢瘫痪或无力的患者恢复肢体活动能力，核心产品面向中风、脊髓损伤及其他神经系统疾病患者，主要市场覆盖北美地区。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
MYO vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.2倍
$11.4M
营收增速更快
RVSB
高出16.3%
-5.9%
净利率更高
RVSB
高出43.4%
-33.6%
自由现金流更多
RVSB
多$1.6M
$-2.4M
两年增速更快
MYO
近两年复合增速
24.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $11.4M | $14.0M |
| 净利润 | $-3.8M | $1.4M |
| 毛利率 | 68.6% | — |
| 营业利润率 | -24.4% | 12.4% |
| 净利率 | -33.6% | 9.8% |
| 营收同比 | -5.9% | 10.4% |
| 净利润同比 | -1366.4% | 11.8% |
| 每股收益（稀释后） | $-0.09 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MYORVSB
| Q4 25 | $11.4M | $14.0M | ||
| Q3 25 | $10.1M | $13.6M | ||
| Q2 25 | $9.7M | $13.3M | ||
| Q1 25 | $9.8M | $12.9M | ||
| Q4 24 | $12.1M | $12.7M | ||
| Q3 24 | $9.2M | $12.8M | ||
| Q2 24 | $7.5M | $12.2M | ||
| Q1 24 | $3.8M | $9.0M |
净利润MYORVSB
| Q4 25 | $-3.8M | $1.4M | ||
| Q3 25 | $-3.7M | $1.1M | ||
| Q2 25 | $-4.6M | $1.2M | ||
| Q1 25 | $-3.5M | $1.1M | ||
| Q4 24 | $-260.1K | $1.2M | ||
| Q3 24 | $-966.4K | $1.6M | ||
| Q2 24 | $-1.1M | $966.0K | ||
| Q1 24 | $-3.8M | $-3.0M |
毛利率MYORVSB
| Q4 25 | 68.6% | — | ||
| Q3 25 | 63.8% | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.2% | — | ||
| Q4 24 | 71.4% | — | ||
| Q3 24 | 75.4% | — | ||
| Q2 24 | 70.8% | — | ||
| Q1 24 | 61.2% | — |
营业利润率MYORVSB
| Q4 25 | -24.4% | 12.4% | ||
| Q3 25 | -34.9% | 10.2% | ||
| Q2 25 | -47.6% | 11.7% | ||
| Q1 25 | -35.8% | 11.3% | ||
| Q4 24 | -2.0% | 12.4% | ||
| Q3 24 | -10.4% | 15.5% | ||
| Q2 24 | -14.8% | 10.0% | ||
| Q1 24 | -103.6% | -47.5% |
净利率MYORVSB
| Q4 25 | -33.6% | 9.8% | ||
| Q3 25 | -36.3% | 8.1% | ||
| Q2 25 | -48.0% | 9.2% | ||
| Q1 25 | -35.2% | 8.9% | ||
| Q4 24 | -2.2% | 9.7% | ||
| Q3 24 | -10.5% | 12.2% | ||
| Q2 24 | -14.9% | 7.9% | ||
| Q1 24 | -102.2% | -34.7% |
每股收益（稀释后）MYORVSB
| Q4 25 | $-0.09 | $0.07 | ||
| Q3 25 | $-0.09 | $0.05 | ||
| Q2 25 | $-0.11 | $0.06 | ||
| Q1 25 | $-0.08 | $0.05 | ||
| Q4 24 | $0.00 | $0.06 | ||
| Q3 24 | $-0.03 | $0.07 | ||
| Q2 24 | $-0.03 | $0.05 | ||
| Q1 24 | $-0.10 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.4M | $28.6M |
| 总债务越低越好 | $11.2M | — |
| 股东权益账面价值 | $11.4M | $164.2M |
| 总资产 | $38.6M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.98× | — |
8季度趋势，按日历期对齐
现金及短期投资MYORVSB
| Q4 25 | $18.4M | $28.6M | ||
| Q3 25 | $12.6M | $32.8M | ||
| Q2 25 | $15.5M | $34.2M | ||
| Q1 25 | $21.5M | $29.4M | ||
| Q4 24 | $24.9M | $25.3M | ||
| Q3 24 | $6.6M | $31.0M | ||
| Q2 24 | $9.0M | $27.8M | ||
| Q1 24 | $11.0M | $23.6M |
总债务MYORVSB
| Q4 25 | $11.2M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MYORVSB
| Q4 25 | $11.4M | $164.2M | ||
| Q3 25 | $14.6M | $163.5M | ||
| Q2 25 | $17.6M | $162.0M | ||
| Q1 25 | $21.7M | $160.0M | ||
| Q4 24 | $24.7M | $158.3M | ||
| Q3 24 | $9.3M | $160.8M | ||
| Q2 24 | $9.7M | $155.9M | ||
| Q1 24 | $10.9M | $155.6M |
总资产MYORVSB
| Q4 25 | $38.6M | $1.5B | ||
| Q3 25 | $34.1M | $1.5B | ||
| Q2 25 | $38.7M | $1.5B | ||
| Q1 25 | $40.9M | $1.5B | ||
| Q4 24 | $42.2M | $1.5B | ||
| Q3 24 | $16.3M | $1.5B | ||
| Q2 24 | $16.2M | $1.5B | ||
| Q1 24 | $16.5M | $1.5B |
负债/权益比MYORVSB
| Q4 25 | 0.98× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $-736.0K |
| 自由现金流率自由现金流/营收 | -21.0% | -5.2% |
| 资本支出强度资本支出/营收 | 10.9% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-18.7M | $20.4M |
8季度趋势，按日历期对齐
经营现金流MYORVSB
| Q4 25 | $-1.1M | $-506.0K | ||
| Q3 25 | $-1.8M | $16.8M | ||
| Q2 25 | $-8.9M | $-697.0K | ||
| Q1 25 | $-2.7M | $8.3M | ||
| Q4 24 | $3.4M | $2.2M | ||
| Q3 24 | $-1.5M | $764.0K | ||
| Q2 24 | $-1.9M | $5.4M | ||
| Q1 24 | $-3.2M | $12.8M |
自由现金流MYORVSB
| Q4 25 | $-2.4M | $-736.0K | ||
| Q3 25 | $-2.9M | $16.4M | ||
| Q2 25 | $-10.1M | $-773.0K | ||
| Q1 25 | $-3.3M | $5.6M | ||
| Q4 24 | $2.5M | $1.9M | ||
| Q3 24 | $-1.8M | $-1.4M | ||
| Q2 24 | $-2.0M | $5.3M | ||
| Q1 24 | $-3.3M | $7.1M |
自由现金流率MYORVSB
| Q4 25 | -21.0% | -5.2% | ||
| Q3 25 | -28.6% | 120.1% | ||
| Q2 25 | -104.9% | -5.8% | ||
| Q1 25 | -34.0% | 43.1% | ||
| Q4 24 | 20.8% | 15.0% | ||
| Q3 24 | -19.7% | -11.3% | ||
| Q2 24 | -27.1% | 43.7% | ||
| Q1 24 | -88.0% | 79.0% |
资本支出强度MYORVSB
| Q4 25 | 10.9% | 1.6% | ||
| Q3 25 | 10.4% | 2.9% | ||
| Q2 25 | 13.0% | 0.6% | ||
| Q1 25 | 6.8% | 21.0% | ||
| Q4 24 | 7.1% | 2.4% | ||
| Q3 24 | 3.5% | 17.3% | ||
| Q2 24 | 1.6% | 0.9% | ||
| Q1 24 | 1.6% | 62.0% |
现金转化率MYORVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MYO
| Direct To Patient | $7.9M | 69% |
| Clinical And Medical Providers | $3.5M | 31% |
RVSB
暂无分部数据
